APPLICATION
Application Note
The peptide is used for blocking the antibody activity of survivin antibodies. Itusually blocks the antibody activity completely in Western blot by incubating the peptide withequal volume of antibody for 30 min at 37ºC
PROPERTIES
Form
Liquid
Buffer
PBS, 0.1% BSA
Preservative
0.02% Sodium azide
Storage
Store the peptide at -20ºC, stable for one year.
Concentration
0.20 mg/ml (Please refer to the vial label for the specific concentration.)
Conjugation
Unconjugated
Note
For laboratory research use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.
Purchasers shall not, and agree not to enable third parties to, analyze, copy, reverse engineer or otherwise attempt to determine the structure or sequence of the product.
TARGET
Synonyms
Baculoviral Iap Repeat Containing 5 , Api4 , Epr-1 , Birc5
Background
Survivin, a new inhibitor of apoptosis (IAP) protein, is expressed in the G2 / M phase of the cell cycle in a cycle regulated manner. At the beginning of mitosis, survivin associates with microtubules of the mitotic spindle in a specific and saturable reaction that is regulated by microtubule dynamics. Disruption of survivin microtubule interactions results in loss of survivin's anti apoptosis function and increased caspase 3 activity, a mechanism involved in cell death, during mitosis. It indicates that survivin may counteract a default induction of apoptosis in G2 / M phase. The over expression of survivin in cancer may overcome this apoptotic checkpoint and favour aberrant progression of transformed cells through mitosis.
Research Area
REFERENCE
There are currently no references for Survivin peptide (GTX27866). Be the first to share your publications with this product.
REVIEW
There are currently no reviews for Survivin peptide (GTX27866). Be the first to share your experience with this product.